BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21769427)

  • 1. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
    Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
    Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA profile analysis of human prostate cancers.
    Tong AW; Fulgham P; Jay C; Chen P; Khalil I; Liu S; Senzer N; Eklund AC; Han J; Nemunaitis J
    Cancer Gene Ther; 2009 Mar; 16(3):206-16. PubMed ID: 18949015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
    Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
    Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.
    Leite KR; Sousa-Canavez JM; Reis ST; Tomiyama AH; Camara-Lopes LH; Sañudo A; Antunes AA; Srougi M
    Urol Oncol; 2011; 29(3):265-9. PubMed ID: 19372056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
    Martens-Uzunova ES; Jalava SE; Dits NF; van Leenders GJ; Møller S; Trapman J; Bangma CH; Litman T; Visakorpi T; Jenster G
    Oncogene; 2012 Feb; 31(8):978-91. PubMed ID: 21765474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
    Vis AN; Schröder FH; van der Kwast TH
    Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.
    Barron N; Keenan J; Gammell P; Martinez VG; Freeman A; Masters JR; Clynes M
    Prostate; 2012 Aug; 72(11):1193-9. PubMed ID: 22161972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
    J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression signatures that correlated with Gleason score and relapse in prostate cancer.
    Bibikova M; Chudin E; Arsanjani A; Zhou L; Garcia EW; Modder J; Kostelec M; Barker D; Downs T; Fan JB; Wang-Rodriguez J
    Genomics; 2007 Jun; 89(6):666-72. PubMed ID: 17459658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.